COCP earnings date and last-quarter result: next report 2026-08-13, last quarter miss, P/E -1.27. Updated 2026-07-23.
Cocrystal Pharma (COCP) Research Hub
Cocrystal Pharma (COCP) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 0.9719 USD (+2.31%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.27, market cap 0.01B. This hub links to the full technical, earnings and options research available for COCP.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 0.9719 USD (+2.31%) |
| 52-week range | 0.76 USD – 1.29 USD |
| Trend regime | Range |
| 14-day RSI | 28.4 (Oversold) |
| Trailing P/E | -1.27 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for COCP
Covered Call on COCP: how it works, illustrative setup around the real 0.9719 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on COCP: how it works, illustrative setup around the real 0.9719 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on COCP: how it works, illustrative setup around the real 0.9719 USD price, max profit/loss, breakeven and when to use it. Educational.
COCP technical analysis: range, last 0.9719 USD, RSI 28.4, 52w range 0.76 USD–1.29 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is COCP in?
Cocrystal Pharma (COCP) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is COCP in an uptrend or downtrend?
As of 2026-10-26, COCP is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is COCP's trailing P/E ratio?
COCP's trailing P/E is -1.27, with a market cap of 0.01B. See the earnings research page for full valuation detail.
When does COCP next report earnings?
COCP is next scheduled to report earnings on 2026-08-13.